Oppenheimer analyst Francois Brisebois upgraded DiaMedica Therapeutics to Outperform from Perform with a $7 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DMAC:
Oppenheimer analyst Francois Brisebois upgraded DiaMedica Therapeutics to Outperform from Perform with a $7 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DMAC: